TrianglePSCA-Targeting CAR-T Cells (NCT05805371)
PSCA-Targeting CAR-T Cells trial for Castration-Resistant Prostate Carcinoma (NCT05805371). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for metastatic castration resistant prostate cancer whose tumors carry a protein called PSCA, in men 18 and older.
The idea: give a patient's own T cells a new target. T cells are collected from the blood, engineered to recognize PSCA, and returned by infusion, up to three times, after lymphodepleting chemotherapy. One group also receives radiation to the metastases.
This phase 1b study plans 21 patients, and safety comes first. At City of Hope in Duarte, Tanya Dorff leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.